Disruption of the unfolded protein response (UPR) by lead compound selectively suppresses cancer cell growth
Disruption of the unfolded protein response (UPR) by lead compound selectively suppresses cancer cell growth
复制标题
先导化合物破坏未折叠蛋白反应(UPR)可选择性抑制癌细胞生长
DOI:
10.1016/j.canlet.2015.02.029
复制
发表时间:
2015-05-01
期刊:
影响因子:
9.7
通讯作者:
Li, Jia
中科院分区:
文献类型:
--
作者:
Huang, Hejing;Liu, Huanan;Li, Jia
Identifying chemotherapy candidates with high selectivity against cancer cells is a major challenge in cancer treatment. Tumor microenvironments cause chronic endoplasmic reticulum (ER) stress and activate the unfolded protein response (UPR) as an adaptive response. Here, one novel small-molecule compound, 17#, was discovered as a potent pan-UPR inhibitor. It exhibited good selection for growth inhibition when cancer cells were cultured in 2-deoxy-D-glucose (2DG), mimicking an in vitro glucose-deprived status. Additionally, 17# alone could mildly suppress the growth of HeLa tumor xenografts, and a synergistic anti-cancer effect was observed when 17# was combined with 2DG. A mechanistic study showed that 17#-induced selective anti-cancer effects were highly dependent on UPR inhibition, and overexpressing GRP78 or XBP1s reversed the 17#-induced growth inhibition and cell cycle arrest, partially by delaying the downregulation of the cell cycle regulator cyclin B1. Furthermore, 17# improved the sensitivity of anti-cancer drugs such as doxorubicin or etoposide. Our study presents evidence that disrupting the UPR has selective therapeutic potential and may enhance drug sensitivity. (C) 2015 Elsevier Ireland Ltd. All rights reserved.